Eris Lifesciences Limited (BOM:540596)
1,417.70
+33.70 (2.43%)
At close: Jan 22, 2026
Eris Lifesciences Revenue
Eris Lifesciences had revenue of 7.90B INR in the quarter ending September 30, 2025, with 6.93% growth. This brings the company's revenue in the last twelve months to 29.86B, up 20.16% year-over-year. In the fiscal year ending March 31, 2025, Eris Lifesciences had annual revenue of 28.79B with 44.59% growth.
Revenue (ttm)
29.86B
Revenue Growth
+20.16%
P/S Ratio
6.58
Revenue / Employee
8.90M
Employees
3,354
Market Cap
196.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 28.79B | 8.88B | 44.59% |
| Mar 31, 2024 | 19.91B | 3.29B | 19.83% |
| Mar 31, 2023 | 16.62B | 3.36B | 25.31% |
| Mar 31, 2022 | 13.26B | 1.34B | 11.20% |
| Mar 31, 2021 | 11.93B | 1.34B | 12.71% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 76.18B |
| Granules India | 48.42B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| GlaxoSmithKline Pharmaceuticals | 37.09B |
| Caplin Point Laboratories | 20.42B |
| AstraZeneca Pharma India | 20.06B |
| Sanofi India | 19.33B |
| Viyash Scientific | 16.58B |